Becton, Dickinson and Company (BDX)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Becton, Dickinson as a durable but not cheap medical-supplies franchise. It sells catheters, devices, lab equipment and diagnostics to hospitals and laboratories worldwide, with 72,000 employees and a broad consumables base that should produce recurring demand. The latest filed quarter, fiscal Q3 2026 ended 2026-06-30, showed revenue of $5.0B, net income of $377.0M and diluted EPS of $1.37. But the prior filed quarter, fiscal Q2 2026 ended 2026-03-31, had a net loss of $311.0M, so earnings are uneven. Full-year fiscal 2025 filed revenue was $21.8B and net income $1.7B, versus fiscal 2024 revenue of $20.2B and net income of $1.7B; EPS slipped to $5.82 from $5.86. FairStock calls it a Stalwart—steady growth—though current returns are weak: ROE 6.61%, ROCE 4.34%. The balance sheet has D/E of 0.69, free cash flow is $2.5B, and FairStock's Piotroski F-score is 8/9. Valuation is the rub. At the 2026-10-26 close of $196.39, FairStock shows P/E 34.04, P/B 2.19, EV/EBITDA 15.93, and a Graham Number of $107.88; the price sits far above that conservative anchor, with a -84.38% margin of safety. Altman Z is 1.84, not comforting. This is a decent business with cash generation and scale, but the price already assumes better profits. I would want a wider gap between price and intrinsic value.

In plain English: Becton, Dickinson makes medical supplies, devices, lab equipment, and diagnostic products used by hospitals and laboratories around the world. The business looks sturdy in some ways—it generates about $2.5 billion in cash—but recent profits have been uneven and returns are low. At $196.39, the shares look expensive versus the company's earnings and a conservative value estimate.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-06-30) · fiscal Q2 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-09-30) · FY2024 10-K (period ended 2024-09-30) · FY2023 10-K (period ended 2023-09-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer